Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla ... Warp Speed for cancer.” Bourla has not pitched the idea in those ...
Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...
SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert ... not responded as he would like — Pfizer shares are down 5% over the past 12 months — Bourla ...
Acquiring an injectable GLP-1 drug would not be in Pfizer's interest because "probably it's a little bit too late," Bourla said, referring to Wegovy and Zepbound's class of treatments that target ...
Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing Albert Bourla talks about his employees' effort to develop a COVID-19 vaccine in record ...
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues in 2025, says CEO Albert Bourla. The company achieved its 2024 goal of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback